Analyst Rating Update on Raptor Pharmaceutical (RPTP)

Raptor Pharmaceutical (RPTP) : 5 analysts are covering Raptor Pharmaceutical (RPTP) and their average rating on the stock is 1.8, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Raptor Pharmaceutical (RPTP) : Average target price received by Raptor Pharmaceutical (RPTP) is $7.6 with an expected standard deviation of $2.7. The most aggressive target on the stock is $11, whereas the most downbeat target is $4. 5 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


Raptor Pharmaceutical (NASDAQ:RPTP): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.91 and $5.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.17, notching a gain of 3.87% for the day. The total traded volume was 872,504 . The stock had closed at $5.94 on the previous day.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.